LY2452473 clinical trials
Also written LY2452473.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses LY2452473 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LY2452473
- 3
Studies by the year they started
3 studies that test it; most in 2010 (1)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Eli Lilly and Company (2) · Dana-Farber Cancer Institute (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses LY2452473 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Selective Androgen Receptor Modulator for Symptom Management in Prostate CancerCompletedPhase 2Dana-Farber Cancer InstituteNCT02499497Written as LY2452473
- A Study of LY900010 in Erectile DysfunctionCompletedPhase 2Eli Lilly and CompanyNCT01160289Written as LY2452473
- Disposition of 14C-LY2452473 Following Oral Administration in Healthy Human SubjectsCompletedPhase 1Eli Lilly and CompanyNCT01275157Written as LY2452473
As the comparator · 1 — what is tested is compared with LY2452473
Codes
What other systems call LY2452473 · ClinicalTrials.gg INT006323
- NCI Thesaurus C123792Selective Androgen Receptor Modulator LY2452473One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| NCI Thesaurus | C123792 | Selective Androgen Receptor Modulator LY2452473 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.